OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) has been one of our biggest winners here at Insider Financial over the past few months. We first identified the company as a company with big potential back in October. What attracted us is the company’s focus on medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. Biopharma plays like OWCP are where we believe the greatest potential lies for cannabis investors. The perfect example is GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) and its $3.27 billion market cap.
OWCP still has a long way to go to catch GWPH. OWCP has a current market cap of just $129 million. However, if you look at the long-term chart of GWPH, look at where GWPH was at just three years ago.
The are only a handful of publicly-traded companies focused on cannabinoid-based, pharmaceutical development for investors to bet on. In looking for the right companies, probably the best place in the world for cannabis research is Israel. According to The Cannabist, “Unlike the U.S. government, the Israeli government has had few restrictions on doing research on cannabis, whether basic science or clinical studies.” OWCP says that its research division “leverages the Company’s extensive network comprising some of Israel’s leading researchers, scientists, universities and hospitals, as well as cannabis breeders and extractors, to study and test the effectiveness of different combinations of cannabinoids in the treatment of disease and chronic conditions.”
It helps that OWCP’s Chief Scientific Officer is Dr. Yehuda Baruch. He founded, implemented and led the Israeli Medical Cannabis Unit under the Minister of Health for over 10 years. It’s these types of relationships that have allowed OWCP to sign three research collaboration and license agreements with Sheba Academic Medical Center, Tel Hashomer, Israel. Sheba is a university-affiliated hospital that serves as Israel’s national medical center and the most comprehensive medical center in the Middle East.
OWCP’s primary asset, and the one that we think will drive the most near-term value, is a psoriasis cream. It is a topical compound designed to ensure the effective delivery and dosage of a proprietary cannabinoid-based topical cream, and it is basically in its final round of efficacy testing before it hits the shelves. The company expects to have it commercially available in the US and Israel by the end of the first quarter, with a sales push starting second quarter.
Beyond psoriasis, OWC is also pushing a multiple myeloma candidate through early stage trials, with the goal of getting the asset in question into clinical studies before the end of this year. Multiple myeloma is a large unmet need both domestically in the US and abroad, and the news stream alone associated with getting a drug into the clinical phase that targets this condition is worth considerable upside to a company of OWCP’s size.
Finally, OWCP is also working on a sublingual tablet designed to offer physicians a measurable and quantifiable method of dosing patients with cannabis related treatments. The current primary dosing method is smoking, but most agree that this is very inefficient. It’s also tough to track from a physician perspective. OWCP’s asset aims to resolve this problem, and the company is looking to carry it into clinical trials for a range of conditions – posttraumatic stress disorder, fibromyalgia and the above discussed multiple myeloma to name just three – over the coming 12 months.
The next update we should be getting from the company will be at the Wall Street Conference on March 1. Ziv Turner, OWCP’s VP Business development and Managing Director of One World Cannabis, will be presenting at the conference. Prior to the conference, he said:
“The Wall Street Conference is one of the leading conferences for small-cap investors and OWC is excited to be a part of it. OWC continues to make significant progress in the research and development of cannabis-centric medical treatments, specifically with our psoriasis cream, which is being readied for the U.S. and European markets. We are focused on having our products on the shelves in the MMJ states this year. I am very much looking forward to discussing the Company with conference attendees.”
OWCP is one of the most exciting plays for cannabis investors in the entire space right now. The company owns its IP and there’s significant value in the IP alone. As the company makes it way through the approval and commercialization process, its value will increase exponentially. With an experienced management team and a strong advisory board, OWCP has positioned itself to achieve its goals.
We will be updating our subscribers as soon as we know more. For the latest updates on OWCP, sign up below!
Disclosure: We have no position in OWCP or GWPH and have not been compensated for this article.